Why human lifespan is rapidly increasing: Solving "longevity riddle" with "revealed-slow-aging" hypothesis

Aging

Volumn 2, Issue 4, 2010, Pages 177-182

  Blagosklonny, Mikhail V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Aging; Diseases; Health span; Lifespan; Longevity; MTOR; Rapamycin; Senescence

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

AGED; AGING; ARTICLE; BIOLOGICAL MODEL; GENETICS; HUMAN; LONGEVITY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AGED; AGING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LONGEVITY; MODELS, BIOLOGICAL; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 78049499910     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100139     Document Type: Article

References (31)

1. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging 2009; 1: 281-288.
2. Wilmoth JR, Deegan LJ, Lundstrom H, Horiuchi S. Increase of maximum life-span in Sweden, 1861-1999. Science. 2000; 289: 2366-2368. Figure 4. Anti-aging drugs will delay the onset of deterioration without affecting deterioration.
3. Vaupel JW. Biodemography of human ageing. Nature. 2010; 464: 536-542.
4. Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science. 2002; 296: 1029-1031.
5. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009; 374: 1196-1208.
6. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006, 5: 2087-2102.
7. Blagosklonny MV. Aging: ROS or TOR. Cell Cycle. 2008; 7: 3344-3354.
8. Blagosklonny MV. TOR-driven aging: speeding car without brakes. Cell Cycle. 2009; 8: 4055-4059.
9. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926-1945.
10. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124: 471-484.
11. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? Aging. 2009; 586-597.
12. Blagosklonny MV and Hall MN. Growth and aging: a common molecular mechanism. Aging. 2009; 1: 357-362.
13. Demidenko ZN and Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008; 7: 3355-3361.
14. Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacological deceleration. Cell Cycle. 2009; 8: 1883-1887
15. Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004; 35: 1144-1156.
16. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today. 2007; 12: 218-224.
17. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther. 2008; 7: 1520-1524.
18. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA, Basso MD, Adelman SJ. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant. 2003; 3: 562-569.
19. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis. 2004; 172: 31-38.
20. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol. 2005; 46: 481-486.
21. Gadioli AL, Nogueira BV, Arruda RM, Pereira RB, Meyrelles SS, Arruda JA, Vasquez EC. Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice. Braz J Med Biol Res. 2009; 42: 1191-1195.
22. Zhao L, Ding T, Cyrus T, Cheng Y, Tian H, Ma M, Falotico R, Pratico D. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. Br J Pharmacol. 2009; 156: 774-785.
23. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis. 2008; 198: 39-48.
24. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandezr E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature. 2009; 460: 392-396.
25. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV. Rapamycin Extends Maximal Lifespan in Cancer-Prone Mice. Am J Pathol. 2010; in press
26. Moskalev AA, Shaposhnikov MV. Pharmacological Inhibition of Phosphoinositide 3 and TOR Kinases Improves Survival of Drosophila melanogaster. Rejuvenation Res. 2009; in press
27. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab. 2010; 11: 35-46.
28. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460: 108-112.
29. Finch CE, Crimmins EM. Inflammatory exposure and historical changes in human life-spans. Science. 2004; 305: 1736-1739.
30. Crimmins EM, Finch CE. Infection, inflammation, height, and longevity. Proc Natl Acad Sci U S A. 2006; 103: 498-503.
31. Taleb NN. The black swan: the impact of the highly improbable. 2007. Random House, New York.